Seres Therapeutics (NASDAQ:MCRB) Hits New 12-Month Low - Here's What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $7.18 and last traded at $8.16, with a volume of 275773 shares traded. The stock had previously closed at $7.48.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MCRB shares. StockNews.com cut Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, April 10th. Chardan Capital reaffirmed a "buy" rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Thursday, March 20th. Finally, The Goldman Sachs Group lowered their price target on Seres Therapeutics from $1.00 to $0.75 and set a "sell" rating on the stock in a report on Friday, March 14th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $4.00.

Seres Therapeutics Trading Up 9.1 %

The company has a market cap of $1.42 billion, a price-to-earnings ratio of -35.48 and a beta of 2.54. The company's 50 day moving average price is $0.83 and its 200 day moving average price is $0.82.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after buying an additional 43,700 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock worth $1,314,000 after purchasing an additional 255,014 shares during the period. Virtu Financial LLC increased its holdings in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 18,191 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company's stock valued at $780,000 after purchasing an additional 543,469 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Seres Therapeutics by 15.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after buying an additional 117,107 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company's stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.